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The outcomes of traditional therapy, targeted
therapy, or immunotherapy for cancer are influenced by the differences in cancer mutational
profiles. Tumors with mismatch-repair deficiency
have specific mutational profiles characterized
by high microsatellite instability (MSI). (Microsatellites are stretches of DNA made up of short
tandem repeats scattered throughout the human
genome; the number of repeats composing any
given microsatellite varies from person to person.) A study recently reported by Mandal and
colleagues1 shows that both the degree of MSI in
tumor tissue and the resultant tumor mutational
burden, especially the burden of a particular type
of mutation, correlate with and therefore may
help predict a response to antibodies against programmed death 1 (anti–PD-1) immunotherapy.
Microsatellites are prone to DNA replication
errors, which are usually repaired in normal
cells. In cells with defective DNA mismatchrepair genes, however, the “errors” accumulate,
leading to somatic microsatellite polymorphisms,
or MSI.2 MSI has been observed in many types
of cancer but is most prevalent in colorectal,
endometrial, and gastric cancers. Findings of
general correlations among mismatch-repair
deficiency, high tumor mutational burden, high
MSI, and responses to immune checkpoint inhibition led to the approval of anti–PD-1 therapy
solely according to the status of MSI and mismatch repair, rather than cancer type.3 However,
responses to anti–PD-1 therapy vary considerably
among patients who have both mismatch-repair
deficiency and MSI; nearly half these patients
have only limited benefit. To further delineate
the mechanistic details of interactions among
these factors and to reveal the best predictors of
benefit of anti–PD-1 therapy in patients with
mismatch-repair deficiency, Mandal et al. carried
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out experiments in mice. These experiments
were followed by analyses of sequencing results
from the Cancer Genome Atlas project and
clinical data from two patient cohorts.
The high degree of genetic heterogeneity in
mismatch repair–deficient human tumors presents
challenges in identifying causal relationships and
in quantifying contributions of individual elements to the response to PD-1 checkpoint inhibitors. Mandal and colleagues started out by
inactivating the gene Msh2, which is indispensable for normal mismatch repair, in poorly immunogenic mouse melanoma and mouse coloncarcinoma cell lines (Fig. 1). The longer the cell
lines were cultured after becoming mismatch
repair–deficient, the more mutations they accrued: the MSI scores (with higher scores indicating greater genomic instability)4 of cells cultured
for 1 month after Msh2 inactivation were intermediate, whereas the scores of cells cultured for
an additional 3 months were much higher. Cells
with a high MSI score had significantly higher
percentages of newly acquired indel mutations
(insertions or deletions of DNA sequence) than
those with an intermediate MSI score.
In mice treated with anti–PD-1, tumors grown
from the parental and MSI-intermediate lines had
limited responses, but tumors from MSI-high
cells had drastic reductions in volume. These
reductions were accompanied by immune-activation gene-expression signatures in tumor tissue
and by much greater T-cell infiltrations than
those in tumors grown from MSI-intermediate
and parental cells. The immune response had a
strong effect on the immunogenic subpopulation within a tumor, leading to the disappearance of some of the mutation-bearing cells in a
phenomenon termed “immunoediting.” Consistent with the hypothesis that cells with indel
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Figure 1. Microsatellite Instability, Mutation, and Immune Checkpoint Inhibition.
As shown in Panel A, the engagement of programmed death 1 (PD-1) on T cells by the PD-1 ligand (PD-L1) leads to suppression of the
immune response. Antibodies against programmed death 1 (anti–PD-1) disrupt this interaction, allowing the T cells to recognize and
attack tumor cells expressing immunogenic neoepitopes. As shown in Panel B, mismatch repair–deficient tumor cells were created from
competent parental cell lines through CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats associated with Cas9
endonuclease)–mediated knockout of Msh2. These mismatch repair–deficient cells were cultured for 1 month, during which time they
accumulated mutations and became microsatellite instability (MSI)–intermediate cells. Those cultured for 4 months became MSI-high
cells. MSI-high cells accumulated more mutations (indels in particular) than did MSI-intermediate cells. After implantation into immunocompetent mouse hosts and treatment with control or anti–PD-1 antibodies, T-cell infiltration was greater in tumor grafts with anti–
PD-1 treatment. In addition, the relative reduction of novel indels in the shrunken anti–PD-1-treated, MSI-high tumors (as compared with
the number of novel indels in the control-treated MSI-high tumors) is consistent with “immunoediting.” The numbers of new variants
were determined with the use of the genome sequence of the parental cell line as a control. The bar graphs are meant to convey trends
and are not intended to be precise. MHC denotes major histocompatibility complex, and SNV single-nucleotide variant.
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Clinical Implications of Basic Research

mutations have a higher probability of generating immunogenic neoantigens than do those
with more single-nucleotide variants, and that
the former are more likely to be targeted by
T cells, there was a greater loss of indels than
single-nucleotide variants in the MSI-high tumors in mice treated with anti–PD-1.
With these new findings from their murine
models, the investigators next looked for the
best predictor of outcomes of anti–PD-1 therapy
in cohorts of human patients. They observed a
general trend of higher cytolytic scores (indicating increased cytolytic activity of T cells) in MSIhigh tumors than in MSI-low tumors across 14
different types of cancer in the Cancer Genome
Atlas data set. The authors focused on 9 patients
who had MSI-high colorectal tumors with a wide
range of MSI scores, and they looked for correlations between clinical outcomes of anti–PD-1
therapy (pembrolizumab5) and the mutational
characteristics of the tumors. These analyses
showed that both a higher MSI score and a
higher indel load in tumors were associated with
better clinical outcomes in patients who received
immune checkpoint blockade therapy. In contrast, they observed no significant association
between numbers of single-nucleotide variants
and clinical outcomes. In another small, retrospective analysis, 33 patients — each with a
mismatch repair–deficient tumor (colorectal or
esophagogastric carcinoma) and all of whom
received a PD-1 checkpoint inhibitor — had longer survival if they had an MSI-high tumor than
if they had an MSI-intermediate tumor.
Although immunostaining of mismatch-repair
proteins in tumor tissue and detection of MSI
markers by the polymerase chain reaction will
continue to be helpful in clinical testing, the
results reported by Mandal et al. support the use
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of MSI scoring and tumor mutational burden
(especially the indel load), which can be quantified by next-generation DNA sequencing, to predict the outcome of anti–PD-1 immunotherapy.
These new approaches require validation in
larger, independent clinical studies, and a key
area for further investigation will be their clinical validity in predicting long-term responses.
Although MSI-high tumors with a high load of
indel mutations shrank with immune checkpoint blockade in mice, they were not entirely
eradicated, nor were they eliminated in most of
the human patients. Immunoediting during
therapy may preferentially remove the more immunogenic cancer subclones, leaving behind less
immunogenic subclones that go on to form a
recurrent tumor — in which case, a combinatorial therapy with a treatment method other than
immunotherapy would appear to be warranted.
Disclosure forms provided by the authors are available at
NEJM.org.
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